Multiple sclerosis and virus induced immune responses: Autoimmunity can be primed by molecular mimicry and augmented by bystander activation

Autoimmunity

Volumn 39, Issue 1, 2006, Pages 9-19

  McCoy, Lori ^a   Tsunoda, Ikuo ^a   Fujinami, Robert S ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Autoimmune diseases; Experimental allergic encephalomyelitis; Immunological models; Myelin proteolipid protein; Virology; Virus diseases

Indexed keywords

ALPHA INTERFERON; BETA INTERFERON; BETA1A INTERFERON; BRAIN PROTEIN; FREUND ADJUVANT; GAMMA INTERFERON; INTERLEUKIN 12; INTERLEUKIN 12 ANTIBODY; INTERLEUKIN 23; LISOFYLLINE; VIRUS PROTEIN;

ADOPTIVE IMMUNOTHERAPY; ALLERGIC ENCEPHALOMYELITIS; ANTIGEN SPECIFICITY; ARTICLE; AUTOIMMUNITY; BYSTANDER EFFECT; CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOKINE PRODUCTION; CYTOMEGALOVIRUS; CYTOTOXIC T LYMPHOCYTE; DEMYELINATING DISEASE; DENDRITIC CELL; DISEASE ASSOCIATION; DISEASE COURSE; DISEASE EXACERBATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; GENE VECTOR; GENETIC SUSCEPTIBILITY; HUMAN; IMMUNE DEFICIENCY; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; IMMUNOREACTIVITY; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; MOLECULAR MIMICRY; MULTIPLE SCLEROSIS; NATURAL KILLER CELL; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; RISK FACTOR; T LYMPHOCYTE ACTIVATION; VACCINIA VIRUS; VIRAL GENE THERAPY; VIRUS INFECTION; VIRUS STRAIN;

ANIMALS; HUMANS; MOLECULAR MIMICRY; MULTIPLE SCLEROSIS; VIRUS DISEASES;

EID: 33745070952     PISSN: 08916934     EISSN: 1607842X     Source Type: Journal    
DOI: 10.1080/08916930500484799     Document Type: Article

References (119)

1. Dejong, RN. (1970) Multiple sclerosis. History, definition and general considerations. In Multiple sclerosis and other demyelinating diseases. (pp. 45-62). Amsterdam: North-Holland Publishing Company.
2. Noseworthy, JH and Lucchinetti, C and Rodriguez, M and Weinshenker, BG. (2000) Multiple sclerosis N Engl J Med, 343, pp. 938-952.
3. Markovic-Plese, S and McFarland, HF. (2001) Immunopathogenesis of the multiple sclerosis lesion Curr Neurol Neurosci Rep, 1, pp. 257-262.
4. Bitsch, A and Schuchardt, J and Bunkowski, S and Kuhlmann, T and Brück, W. (2000) Acute axonal injury in multiple sclerosis. Correlation with demyelination and inflammation Brain, 123, pp. 1174-1183.
5. Sobel, RA. (1989) T-lymphocyte subsets in the multiple sclerosis lesion Res Immunol, 140, pp. 208-211.
6. Kurtzke, JF. (1997) The epidemiology of multiple sclerosis. In Multiple sclerosis: Clinical and pathogenetic basis. (pp. 91-140). London: Chapman & Hall.
7. Ebers, GC and Bulman, DE and Sadovnick, AD and Paty, DW and Warren, S and Hader, W and Murray, TJ and Seland, TP and Duquette, P and Grey, T and Nelson, R and Nicolle, M and Brunet, D. (1986) A population-based study of multiple sclerosis in twins N Engl J Med, 315, pp. 1638-1642.
8. Sadovnick, AD and Armstrong, H and Rice, GPA and Bulman, D and Hashimoto, L and Paty, DW and Hashimoto, SA and Warren, S and Hader, W and Murray, TJ. (1993) A population-based study of multiple sclerosis in twins: Update Ann Neurol, 33, pp. 281-285.
9. Mumford, CJ and Wood, NW and Kellar-Wood, H and Thorpe, JW and Miller, DH and Compston, DA. (1994) The British Isles survey of multiple sclerosis in twins Neurology, 44, pp. 11-15.
10. Andersen, O and Lygner, PE and Bergstrom, T and Andersson, M and Vahlne, A. (1993) Viral infections trigger multiple sclerosis relapses: A prospective seroepidemiological study J Neurol, 240, pp. 417-422.
11. Edwards, S and Zvartau, M and Clarke, H and Irving, W and Blumhardt, LD. (1998) Clinical relapses and disease activity on magnetic resonance imaging associated with viral upper respiratory tract infections in multiple sclerosis J Neurol Neurosurg Psychiatry, 64, pp. 736-741.
12. Panitch, HS. (1994) Influence of infection on exacerbations of multiple sclerosis Ann Neurol, 36(Suppl), pp. S25-S28.
13. Sibley, WA and Bamford, CR and Clark, K. (1985) Clinical viral infections and multiple sclerosis Lancet, 1, pp. 1313-1315.
14. Johnson, RT. (1998) Chronic inflammatory and demyelinating diseases. In Viral infections of the nervous system2. (pp. 227-263). Philadelphia and New York: Lippincott-Raven Publishers.
15. Fujinami, RS and Oldstone, MBA and Wroblewska, Z and Frankel, ME and Koprowski, H. (1983) Molecular mimicry in virus infection: Crossreaction of measles virus phosphoprotein or of herpes simplex virus protein with human intermediate filaments Proc Natl Acad Sci USA, 80, pp. 2346-2350.
16. Fujinami, RS and Oldstone, MBA. (1985) Amino acid homology between the encephalitogenic site of myelin basic protein and virus: Mechanism for autoimmunity Science, 230, pp. 1043-1045.
17. Deshpande, SP and Lee, S and Zheng, M and Song, B and Knipe, D and Kapp, JA and Rouse, BT. (2001) Herpes simplex virus-induced keratitis: Evaluation of the role of molecular mimicry in lesion pathogenesis J Virol, 75, pp. 3077-3088.
18. von Herrath, MG and Fujinami, RS and Whitton, JL. (2003) Microorganisms and autoimmunity: Making the barren field fertile? Nat Rev Microbiol, 1, pp. 151-157.
19. Martin, R and Utz, U and Coligan, JE and Richert, JR and Flerlage, M and Robinson, E and Stone, R and Biddison, WE and McFarlin, DE and McFarland, HF. (1992) Diversity in fine specificity and T cell receptor usage of the human CD4+ cytotoxic T cell response specific for the immunodominant myelin basic protein peptide 87-106 J Immunol, 148, pp. 1359-1366.
20. Burns, J and Rosenzweig, A and Zweiman, B and Lisak, RP. (1983) Isolation of myelin basic protein-reactive T-cell lines from normal human blood Cell Immunol, 81, pp. 435-440.
21. Richert, JR and McFarlin, DE and Rose, JW and McFarland, HF and Greenstein, JI. (1983) Expansion of antigen-specific T cells from cerebrospinal fluid of patients with multiple sclerosis J Neuroimmunol, 5, pp. 317-324.
22. Chou, YK and Vainiene, M and Whitham, R and Bourdette, D and Chou, CH and Hashim, G and Offner, H and Vandenbark, AA. (1989) Response of human T lymphocyte lines to myelin basic protein: Association of dominant epitopes with HLA class II restriction molecules J Neurosci Res, 23, pp. 207-216.
23. Martin, R and Jaraquemada, D and Flerlage, M and Richert, J and Whitaker, J and Long, EO and McFarlin, DE and McFarland, HF. (1990) Fine specificity and HLA restriction of myelin basic protein-specific cytotoxic T cell lines from multiple sclerosis patients and healthy individuals J Immunol, 145, pp. 540-548.
24. Pette, M and Fujita, K and Kitze, B and Whitaker, JN and Albert, E and Kappos, L and Wekerle, H. (1990) Myelin basic protein-specific T lymphocyte lines from MS patients and healthy individuals Neurology, 40, pp. 1770-1776.
25. Wucherpfennig, KW and Ota, K and Endo, N and Seidman, JG and Rosenzweig, A and Weiner, HL and Hafler, DA. (1990) Shared human T cell receptor Vβ usage to immunodominant regions of myelin basic protein Science, 248, pp. 1016-1019.
26. Olsson, T and Zhi, WW and Hojeberg, B and Kostulas, V and Jiang, YP and Anderson, G and Ekre, HP and Link, H. (1990) Autoreactive T lymphocytes in multiple sclerosis determined by antigen-induced secretion of interferon-γ J Clin Investig, 86, pp. 981-985.
27. Tsunoda, I and Fujinami, RS. (1996) Two models for multiple sclerosis: Experimental allergic encephalomyelitis and Theiler's murine encephalomyelitis virus J Neuropathol Exp Neurol, 55, pp. 673-686.
28. Wang, L-Y and Theil, DJ and Whitton, JL and Fujinami, RS. (1999) Infection with a recombinant vaccinia virus encoding myelin proteolipid protein causes suppression of chronic relapsing-remitting experimental allergic encephalomyelitis J Neuroimmunol, 96, pp. 148-157.
29. Evavold, BD and Sloan-Lancaster, J and Allen, PM. (1993) Tickling the TCR: Selective T-cell functions stimulated by altered peptide ligands Immunol Today, 14, pp. 602-609.
30. Lang, HLE and Jacobsen, H and Ikemizu, S and Andersson, C and Harlos, K and Madsen, L and Hjorth, P and Sondergaard, L and Svejgaard, A and Wucherpfennig, K and Stuart, DI and Bell, JI and Jones, EY and Fugger, L. (2002) A functional and structural basis for TCR cross-reactivity in multiple sclerosis Nat Immunol, 3, pp. 940-943.
31. Oldstone, MBA and Nerenberg, M and Southern, P and Price, J and Lewicki, H. (1991) Virus infection triggers insulin-dependent diabetes mellitus in a transgenic model: Role of anti-self (virus) immune response Cell, 65, pp. 319-331.
32. Oldstone, MBA and von Herrath, MG and Evans, CF and Horwitz, MS. (1996) Virus-induced autoimmune disease: Transgenic approach to mimic insulin-dependent diabetes mellitus and multiple sclerosis Curr Top Microbiol Immunol, 206, pp. 67-83.
33. von Herrath, MG. (2002) Regulation of virally induced autoimmunity and immunopathology: Contribution of LCMV transgenic models to understanding autoimmune insulin-dependent diabetes mellitus Curr Top Microbiol Immunol, 263, pp. 145-175.
34. von Herrath, MG and Oldstone, MBA and Homann, D and Christen, U. (2001) Is activation of autoreactive lymphocytes always detrimental? Viral infections and regulatory circuits in autoimmunity Curr Dir Autoimmun, 4, pp. 91-122.
35. von Herrath, MG and Guerder, S and Lewicki, H and Flavell, RA and Oldstone, MBA. (1995) Coexpression of B7-1 and viral ("self") transgenes in pancreatic β cells can break peripheral ignorance and lead to spontaneous autoimmune diabetes Immunity, 3, pp. 727-738.
36. von Herrath, MG and Oldstone, MBA. (1997) Interferon-γ is essential for destruction of β cells and development of insulin-dependent diabetes mellitus J Exp Med, 185, pp. 531-539.
37. von Herrath, MG and Holz, A. (1997) Pathological changes in the islet milieu precede infiltration of islets and destruction of β-cells by autoreactive lymphocytes in a transgenic model of virus-induced IDDM J Autoimmun, 10, pp. 231-238.
38. Welsh, RM and McNally, JM and Brehm, MA and Selin, LK. (2000) Consequences of cross-reactive and bystander CTL responses during viral infections Virology, 270, pp. 4-8.
39. Brehm, MA and Pinto, AK and Daniels, KA and Schneck, JP and Welsh, RM and Selin, LK. (2002) T cell immunodominance and maintenance of memory regulated by unexpectedly cross-reactive pathogens Nat Immunol, 3, pp. 627-634.
40. +T cells in heterologous antiviral immunity and immunopathology in the lung Nat Immunol, 2, pp. 1067-1076.
41. Selin, LK and Varga, SM and Wong, IC and Welsh, RM. (1998) Protective heterologous antiviral immunity and enhanced immunopathogenesis mediated by memory T cell populations J Exp Med, 188, pp. 1705-1715.
42. Tsunoda, I and Fujinami, RS. (2005) TMEV and neuroantigens: Myelin genes and proteins, molecular mimicry, epitope spreading, and autoantibody-mediated remyelination. In Experimental models of multiple sclerosis. New York: Springer.
43. Tsunoda, I and Fujinami, RS. (1999) Theiler's murine encephalomyelitis virus. In Persistent viral infections. (pp. 517-536). Chichester: John Wiley & Sons Ltd.
44. Fujinami, RS and Zurbriggen, A and Powell, HC. (1988) Monoclonal antibody defines determinant between Theiler's virus and lipid-like structures J Neuroimmunol, 20, pp. 25-32.
45. Yamada, M and Zurbriggen, A and Fujinami, RS. (1990) Monoclonal antibody to Theiler's murine encephalomyelitis virus defines a determinant on myelin and oligodendrocytes, and augments demyelination in experimental allergic encephalomyelitis J Exp Med, 171, pp. 1893-1907.
46. Biron, CA and Cousens, LP and Ruzek, MC and Su, HC and Salazar-Mather, TP. (1998) Early cytokine responses to viral infections and their roles in shaping endogenous cellular immunity Adv Exp Med Biol, 452, pp. 143-149.
47. Biron, CA and Nguyen, KB and Pien, GC and Cousens, LP and Salazar-Mather, TP. (1999) Natural killer cells in antiviral defense: Function and regulation by innate cytokines Annu Rev Immunol, 17, pp. 189-220.
48. Biron, CA. (1998) Role of early cytokines, including alpha and beta interferons (IFN-αβ), in innate and adaptive immune responses to viral infections Semin Immunol, 10, pp. 383-390.
49. Cousens, LP and Orange, JS and Su, HC and Biron, CA. (1997) Interferon-α/β inhibition of interleukin 12 and interferon-γ production in vitro and endogenously during viral infection Proc Natl Acad Sci USA, 94, pp. 634-639.
50. Arnason, BGW. (1996) Interferon beta in multiple sclerosis Clin Immunol Immunopathol, 81, pp. 1-11.
51. Murali-Krishna, K and Altman, JD and Suresh, M and Sourdive, D and Zajac, A and Ahmed, R. (1998) In vivo dynamics of anti-viral CD8 T cell responses to different epitopes. An evaluation of bystander activation in primary and secondary responses to viral infection Adv Exp Med Biol, 452, pp. 123-142.
52. Lin, MY and Selin, LK and Welsh, RM. (2000) Evolution of the CD8 T-cell repertoire during infections Microbes Infect, 2, pp. 1025-1039.
53. Welsh, RM. (2001) Assessing CD8 T cell number and dysfunction in the presence of antigen J Exp Med, 193, pp. F19-F22.
54. Trinchieri, G. (1995) Interleukin-12: A proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity Annu Rev Immunol, 13, pp. 251-276.
55. Orange, JS and Wang, B and Terhorst, C and Biron, CA. (1995) Requirement for natural killer cell-produced interferon γ in defense against murine cytomegalovirus infection and enhancement of this defense pathway by interleukin 12 administration J Exp Med, 182, pp. 1045-1056.
56. Su, HC and Nguyen, KB and Salazar-Mather, TP and Ruzek, MC and Dalod, MY and Biron, CA. (2001) NK cell functions restrain T cell responses during viral infections Eur J Immunol, 31, pp. 3048-3055.
57. Rabinovich, BA and Li, J and Shannon, J and Hurren, R and Chalupny, J and Cosman, D and Miller, RG. (2003) Activated, but not resting, T cells can be recognized and killed by syngeneic NK cells J Immunol, 170, pp. 3572-3576.
58. Xu, W and Fazekas, G and Hara, H and Tabira, T. (2005) Mechanism of natural killer (NK) cell regulatory role in experimental autoimmune encephalomyelitis J Neuroimmunol, 163, pp. 24-30.
59. Kastrukoff, LF and Morgan, NG and Zecchini, D and White, R and Petkau, AJ and Satoh, J-I and Paty, DW. (1998) A role for natural killer cells in the immunopathogenesis of multiple sclerosis J Neuroimmunol, 86, pp. 123-133.
60. Hilliard, B and Wilmen, A and Seidel, C and Liu, TS and Goke, R and Chen, Y. (2001) Roles of TNF-related apoptosis-inducing ligand in experimental autoimmune encephalomyelitis J Immunol, 166, pp. 1314-1319.
61. Takahashi, K and Miyake, S and Kondo, T and Terao, K and Hatakenaka, M and Hashimoto, S and Yamamura, T. (2001) Natural killer type 2 bias in remission of multiple sclerosis J Clin Investig, 107, pp. R23-R29.
62. Orange, JS and Biron, CA. (1996) Characterization of early IL-12, IFN-αβ, and TNF effects on antiviral state and NK cell responses during murine cytomegalovirus infection J Immunol, 156, pp. 4746-4756.
63. Zajac, AJ and Muller, D and Pederson, K and Frelinger, JA and Quinn, DG. (1995) Natural killer cell activity in lymphocytic choriomeningitis virus-infected beta 2-microglobulin-deficient mice Int Immunol, 7, pp. 1545-1556.
64. Bendelac, A and Rivera, MN and Park, SH and Roark, JH. (1997) Mouse CD1-specific NK1 T cells: Development, specificity, and function Annu Rev Immunol, 15, pp. 535-562.
65. Godfrey, DI and Hammond, KJL and Poulton, LD and Smyth, MJ and Baxter, AG. (2000) NKT cells: Facts, functions and fallacies Immunol Today, 21, pp. 573-583.
66. + NKT cells derived from multiple sclerosis in remission Int Immunol, 15, pp. 279-288.
67. α33 invariant T cells in human autoimmune inflammatory lesions in the nervous system Int Immunol, 16, pp. 223-230.
68. Illés, Z and Kondo, T and Newcombe, J and Oka, N and Tabira, T and Yamamura, T. (2000) Differential expression of NK T cell Vα24JαQ invariant TCR chain in the lesions of multiple sclerosis and chronic inflammatory demyelinating polyneuropathy J Immunol, 164, pp. 4375-4381.
69. Mempel, M and Ronet, C and Suarez, F and Gilleron, M and Puzo, G and Van Kaer, L and Lehuen, A and Kourilsky, P and Gachelin, G. (2002) Natural killer T cells restricted by the monomorphic MHC class 1b CD1d1 molecules behave like inflammatory cells J Immunol, 168, pp. 365-371.
70. Sumida, T and Sakamoto, A and Murata, H and Makino, Y and Takahashi, H and Yoshida, S and Nishioka, K and Iwamoto, I and Taniguchi, M. (1995) Selective reduction of T cells bearing invariant Vα24JαQ antigen receptor in patients with systemic sclerosis J Exp Med, 182, pp. 1163-1168.
71. Wilson, SB and Kent, SC and Patton, KT and Orban, T and Jackson, RA and Exley, M and Porcelli, S and Schatz, DA and Atkinson, MA and Balk, SP and Strominger, JL and Hafler, DA. (1998) Extreme Th1 bias of invariant Vα24JαQ T cells in type 1 diabetes Nature, 391, pp. 177-181.
72. + NKT cell numbers are decreased in a wide variety of diseases that are characterized by autoreactive tissue damage Clin Immunol, 100, pp. 144-148.
73. Kojo, S and Adachi, Y and Keino, H and Taniguchi, M and Sumida, T. (2001) Dysfunction of T cell receptor AV24AJ18+, BV11+ double-negative regulatory natural killer T cells in autoimmune diseases Arthritis Rheum, 44, pp. 1127-1138.
74. H2 bias of natural killer T cells Nature, 413, pp. 531-534.
75. +T cells in patients with multiple sclerosis J Neurol Sci, 235, pp. 11-17.
76. Paty, DW and Li, DK. (2001) Interferon beta-lb is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial Neurology, 57, pp. S10-S15. (The UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group)
77. Francis, GS and Rice, GP and Alsop, JC. (2005) Interferon β-1a in MS: Results following development of neutralizing antibodies in PRISMS Neurology, 65, pp. 48-55.
78. Panitch, HS and Hirsch, RL and Haley, AS and Johnson, KP. (1987) Exacerbations of multiple sclerosis in patients treated with gamma interferon Lancet, 1, pp. 893-895.
79. Johnson, KP. (1988) Treatment of multiple sclerosis with various interferons: The cons Neurology, 38, pp. 62-65.
80. Panitch, HS and Hirsch, RL and Schindler, J and Johnson, KP. (1987) Treatment of multiple sclerosis with gamma interferon: Exacerbations associated with activation of the immune system Neurology, 37, pp. 1097-1102.
81. Compston, A. (1988) Treatment and management of multiple sclerosis. In McAlpine's multiple sclerosis3. (pp. 435-498). London: Churchill Livingstone.
82. Reichman, P. (1997) The effects of interferon-β on cytokines and immune responses. In Interferon therapy of multiple sclerosis. (pp. 161-191). New York: Marcel Dekker.
83. Hirsch, RL and Johnson, KP. (1985) The effect of recombinant α2-interferon on defective natural killer cell activity in multiple sclerosis Neurology, 35, pp. 597-600.
84. Rice, GPA and Casali, P and Merigan, TC and Oldstone, MBA. (1983) Natural killer cell activity in patients with multiple sclerosis given α interferon Ann Neurol, 14, pp. 333-338.
85. Traugott, U and Lebon, P. (1988) Multiple sclerosis: Involvement of interferons in lesion pathogenesis Ann Neurol, 24, pp. 243-251.
86. Vartanian, T and Li, Y and Zhao, M and Stefansson, K. (1995) Interferon-γ-induced oligodendrocyte cell death: Implications for the pathogenesis of multiple sclerosis Mol Med, 1, pp. 732-743.
87. Brod, SA and Marshall, GD, Jr and Henninger, EM and Sriram, S and Khan, M and Wolinsky, JS. (1996) Interferon-β1b treatment decreases tumor necrosis factor-α and increases interleukin-6 production in multiple sclerosis Neurology, 46, pp. 1633-1638.
88. Perini, P and Tiberio, M and Sivieri, S and Facchinetti, A and Biasi, G and Gallo, P. (2000) Interleukin-1 receptor antagonist, soluble tumor necrosis factor-α receptor type I and II, and soluble E-selectin serum levels in multiple sclerosis patients receiving weekly intramuscular injections of interferon-β1a Eur Cytokine Netw, 11, pp. 81-86.
89. Ozenci, V and Kouwenhoven, M and Teleshova, N and Pashenkov, M and Fredrikson, S and Link, H. (2000) Multiple sclerosis: Pro- and anti-inflammatory cytokines and metalloproteinases are affected differentially by treatment with IFN-β J Neuroimmunol, 108, pp. 236-243.
90. Rep, MHG and Schrijver, HM and van Lopik, T and Hintzen, RQ and Roos, MTL and Adèr, HJ and Polman, CH and van Lier, RAW. (1999) Interferon (IFN)-β treatment enhances CD95 and interleukin 10 expression but reduces interferon-γ producing T cells in MS patients J Neuroimmunol, 96, pp. 92-100.
91. Rothuizen, LE and Buclin, T and Spertini, F and Trinchard, I and Munafo, A and Buchwalder, P-A and Ythier, A and Biollaz, J. (1999) Influence of interferon β-1a dose frequency on PBMC cytokine secretion and biological effect markers J Neuroimmunol, 99, pp. 131-141.
92. Shi, F-D and Takeda, K and Akira, S and Sarvetnick, N and Ljunggren, H-G. (2000) IL-18 directs autoreactive T cells and promotes autodestruction in the central nervous system via induction of IFN-γ by NK cells J Immunol, 165, pp. 3099-3104.
93. Yasuda, CL and al Sabbagh, A and Oliveira, EC and Diaz-Bardales, BM and Garcia, AA and Santos, LM. (1999) Interferon β modulates experimental autoimmune encephalomyelitis by altering the pattern of cytokine secretion Immunol Invest, 28, pp. 115-126.
94. Monteiro, JM and Harvey, C and Trinchieri, G. (1998) Role of interleukin-12 in primary influenza virus infection J Virol, 72, pp. 4825-4831.
95. Mikloska, Z and Danis, VA and Adams, S and Lloyd, AR and Adrian, DL and Cunningham, AL. (1998) In vivo production of cytokines and β (C-C) chemokines in human recurrent herpes simplex lesions - do herpes simplex virus-infected keratinocytes contribute to their production? J Infect Dis, 177, pp. 827-838.
96. Karp, CL. (1999) Measles: Immunosuppression, interleukin-12, and complement receptors Immunol Rev, 168, pp. 91-101.
97. Beck, J and Rondot, P and Catinot, L and Falcoff, E and Kirchner, H and Wietzerbin, J. (1988) Increased production of interferon gamma and tumor necrosis factor precedes clinical manifestation in multiple sclerosis: Do cytokines trigger off exacerbations? Acta Neurol Scand, 78, pp. 318-323.
98. + T cells to enhance priming for interferon γ production and diminishes interleukin 4 inhibition of such priming Proc Natl Acad Sci USA, 90, pp. 10188-10192.
99. Manetti, R and Parronchi, P and Giudizi, MG and Piccinni, M-P and Maggi, E and Trinchieri, G and Romagnani, S. (1993) Natural killer cell stimulatory factor (interleukin 12 [IL-12]) induces T helper type 1 (Th1)-specific immune responses and inhibits the development of IL-4-producing Th cells J Exp Med, 177, pp. 1199-1204.
100. + T cells from αβ TCR transgenic mice: IL-12 substitution for macrophages to stimulate IFN-γ production is IFN-γ-dependent Int Immunol, 5, pp. 1119-1128.
101. Szabo, SJ and Dighe, AS and Gubler, U and Murphy, KM. (1997) Regulation of the interleukin (IL)-12R β2 subunit expression in developing T helper 1 (Th1) and Th2 cells J Exp Med, 185, pp. 817-824.
102. Magram, J and Connaughton, SE and Warrier, RR and Carvajal, DM and Wu, C-Y and Ferrante, J and Stewart, C and Sarmiento, U and Faherty, DA and Gately, MK. (1996) IL-12-deficient mice are defective in IFNγ production and type 1 cytokine responses Immunity, 4, pp. 471-481.
103. Leonard, JP and Waldburger, KE and Goldman, SJ. (1995) Prevention of experimental autoimmune encephalomyelitis by antibodies against interleukin 12 J Exp Med, 181, pp. 381-386.
104. Brocke, S and Gaur, A and Piercy, C and Gautam, A and Gijbels, K and Fathman, CG and Steinman, L. (1993) Induction of relapsing paralysis in experimental autoimmune encephalomyelitis by bacterial superantigen Nature, 365, pp. 642-644.
105. Constantinescu, CS and Wysocka, M and Hilliard, B and Ventura, ES and Lavi, E and Trinchieri, G and Rostami, A. (1998) Antibodies against IL-12 prevent superantigen-induced and spontaneous relapses of experimental autoimmune encephalomyelitis J Immunol, 161, pp. 5097-5104.
106. Bright, JJ and Du, C and Coon, M and Sriram, S and Klaus, SJ. (1998) Prevention of experimental allergic encephalomyelitis via inhibition of IL-12 signaling and IL-12-mediated Th1 differentiation: An effect of the novel anti-inflammatory drug lisofylline J Immunol, 161, pp. 7015-7022.
107. Pagenstecher, A and Lassmann, S and Carson, MJ and Kincaid, CL and Stalder, AK and Campbell, IL. (2000) Astrocyte-targeted expression of IL-12 induces active cellular immune responses in the central nervous system and modulates experimental allergic encephalomyelitis J Immunol, 164, pp. 4481-4492.
108. Tsunoda, I and Tolley, ND and Theil, DJ and Whitton, JL and Kobayashi, H and Fujinami, RS. (1999) Exacerbation of viral and autoimmune animal models for multiple sclerosis by bacterial DNA Brain Pathol, 9, pp. 481-493.
109. Lankford, CS and Frucht, DM. (2003) A unique role for IL-23 in promoting cellular immunity J Leukoc Biol, 73, pp. 49-56.
110. Cua, DJ and Sherlock, J and Chen, Y and Murphy, CA and Joyce, B and Seymour, B and Lucian, L and To, W and Kwan, S and Churakova, T and Zurawski, S and Wiekowski, M and Lira, SA and Gorman, D and Kastelein, RA and Sedgwick, JD. (2003) Interleukin-23 rather than interleukin-12 is the critical cytokine for autoimmune inflammation of the brain Nature, 421, pp. 744-748.
111. Becher, B and Durell, BG and Noelle, RJ. (2002) Experimental autoimmune encephalitis and inflammation in the absence of interleukin-12 J Clin Investig, 110, pp. 493-497.
112. Gran, B and Zhang, G-X and Yu, S and Li, J and Chen, X-H and Ventura, ES and Kamoun, M and Rostami, A. (2003) IL-12p35-deficient mice are susceptible to experimental autoimmune encephalomyelitis: Evidence for redundancy in the IL-12 system in the induction of central nervous system autoimmune demyelination J Immunol, 169, pp. 7104-7110.
113. Zhang, G-X and Gran, B and Yu, S and Li, J and Siglienti, I and Chen, X and Kamoun, M and Rostami, A. (2003) Induction of experimental autoimmune encephalomyelitis in IL-12 receptor-beta 2-deficient mice: IL-12 responsiveness is not required in the pathogenesis of inflammatory demyelination in the central nervous system J Immunol, 170, pp. 2153-2160.
114. Vandenbroeck, K and Alloza, I and Gadina, M and Matthys, P. (2004) Inhibiting cytokines of the interleukin-12 family: Recent advances and novel challenges J Pharm Pharmacol, 56, pp. 145-160.
115. Li, J and Gran, B and Zhang, GX and Rostami, A and Kamoun, M. (2005) IL-27 subunits and its receptor (WSX-1) mRNAs are markedly up-regulated in inflammatory cells in the CNS during experimental autoimmune encephalomyelitis J Neurol Sci, 232, pp. 3-9.
116. Theil, DJ and Tsunoda, I and Rodriguez, F and Whitton, JL and Fujinami, RS. (2001) Viruses can silently prime for and trigger central nervous system autoimmune disease J NeuroVirol, 7, pp. 220-227.
117. Libbey, JE and Fujinami, RS. (2002) Are virus infections triggers for autoimmune disease? Clin Microbiol News Lett, 24, pp. 73-76.
118. Fairweather, D and Lawson, CM and Chapman, AJ and Brown, CMS and Booth, TWM and Papadimitriou, JM and Shellam, GR. (1998) Wild isolates of murine cytomegalovirus induce myocarditis and antibodies that cross-react with virus and cardiac myosin Immunology, 94, pp. 263-270.
119. Lawson, CM and O'Donoghue, HL and Reed, WD. (1992) Mouse cytomegalovirus infection induces antibodies which cross-react with virus and cardiac myosin: A model for the study of molecular mimicry in the pathogenesis of viral myocarditis Immunology, 75, pp. 513-519.